CLL universally expresses BCL2 (no rearrangement needed; driven by miR-15/16 deletion at...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BCL2-EXPRESSION-CLL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CLL |
| Sources | SRC-CIVIC SRC-ESMO-CLL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BCL2-EXPRESSION-IHC |
|---|---|
| Variant | BCL2 high expression (universal in CLL) |
| Disease | DIS-CLL |
| ESCAT tier | IA |
| Recommended combinations | venetoclax + obinutuzumab (1L), venetoclax + rituximab (R/R), venetoclax + ibrutinib (CAPTIVATE / GLOW) |
| Evidence summary | CLL universally expresses BCL2 (no rearrangement needed; driven by miR-15/16 deletion at 13q14). Venetoclax-based fixed-duration (CLL14: VenO 1L; MURANO: VenR R/R) is FDA/EMA-approved and disease-defining as a target. Not biomarker-selected per se — BCL2 is a CLL-class marker. |
Notes
ESCAT IA. OncoKB Level 1. TLS prophylaxis mandatory at venetoclax ramp-up.
Used By
No reverse references found in the YAML corpus.